757247-93-1

Usage

Uses

Used in Organic Synthesis:
Benzonitrile, 4-amino-2-fluoro-3-methyl(9CI), is used as a building block in organic synthesis for the creation of various chemical compounds. Its unique structure allows for further functionalization and modification, making it a valuable intermediate in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Benzonitrile, 4-amino-2-fluoro-3-methyl(9CI), is used as a starting material or intermediate in the development of new drugs. Its structural features may contribute to the design of novel therapeutic agents with potential applications in various medical fields.

Upstream product

• 127408-03-1 4-bromo-3-fluoro-2-methylbenzenamine 
• 322-33-8 N-(3-fluoro-2-methylphenyl)acetamide 
• 443-86-7 3-fluoro-2-methylaniline 
• 757247-91-9 N-(4-Bromo-3-fluoro-2-methylphenyl)acetamide 
• 757247-92-0 N-(4-Cyano-3-fluoro-2-methylphenyl)acetamide 

Downstream Products

• 757247-94-2 2-Fluoro-4-isocyanato-3-methylbenzonitrile 
• 1114546-30-3 4-bromo-2-fluoro-3-methylbenzonitrile 

Relevant academic research and scientific papers

MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY

Provided herein are Heteroaryl Compounds having the following structure: R2 N (I) or (II) wherein R1 -R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators

Pharmacokinetic studies in cynomolgus monkeys with a novel prototype selective androgen receptor modulator revealed trace amounts of an aniline fragment released through hydrolytic metabolism. This aniline fragment was determined to be mutagenic in an Ames assay. Subsequent concurrent optimization for target activity and avoidance of mutagenicity led to the identification of a pharmacologically superior clinical candidate without mutagenic potential.

BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION

The invention provides compounds according to formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention.